QIAGEN N.V. — FY 2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a separate Q4 filing; the filing does not provide a clear standalone Q4 financial summary. Amounts below are U.S. dollars unless stated otherwise. Financial statements are prepared under U.S. GAAP.
Business context
QIAGEN provides molecular testing products and “Sample to Insight” solutions, including consumables, instruments, automation systems and bioinformatics, to Molecular Diagnostics and Life Sciences customers. Consumables and related revenues were 89% of 2019 sales; instruments were 11%. Molecular Diagnostics represented 48% of sales and Life Sciences 52%.
Key financial metrics
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Net sales | $1,526.4 million | $1,501.8 million |
| Gross profit / margin | $1,005.3 million / 66% | $1,001.0 million / 67% |
| Operating income (loss) | ($26.1 million) | $266.6 million |
| Net income (loss) | ($41.5 million) | $190.4 million |
| Diluted EPS | ($0.18) | $0.82 |
| Cash from operations | $330.8 million | $359.5 million |
| Cash and cash equivalents | $623.6 million | $1,159.1 million |
| Short-term investments | $129.6 million | $234.6 million |
| Working capital | $618.9 million | $1,182.9 million |
| Long-term debt, including current portion | $1,706.4 million | $2,174.2 million |
| Total assets / equity | $5,235.6 million / $2,536.6 million | $5,748.3 million / $2,635.0 million |
Net cash used in investing activities was $222.3 million; financing activities used $639.1 million. Cash, cash equivalents and restricted cash ended the year at $629.4 million. The company also had $479.2 million of undrawn credit facilities. No regular cash dividend was paid or planned for the foreseeable future.
Material changes versus 2018
- Sales increased 2% as reported; adverse currency movements reduced growth by approximately two percentage points. Consumables and related revenues rose 3%, while instrument revenue fell 8%.
- Gross margin declined to 66% from 67%, in part because acquisition-related intangible amortization in cost of sales rose to $71.5 million from $56.7 million.
- Operating results swung to a loss, principally reflecting $199.8 million of restructuring, acquisition, integration and other expense and $140.0 million of long-lived asset impairments. The charges included $138.8 million of impairments associated with suspending development of NGS instrument systems.
- Operating cash flow declined $28.7 million. Cash and working capital also fell substantially, while debt decreased by about $467.9 million, including repayment of the 2019 convertible notes and U.S. private placement debt.
- Sales by customer class: Molecular Diagnostics grew 1% to $737 million; Life Sciences grew 2% to $789 million. QuantiFERON-TB sales grew 8% to $240 million; NGS-related sales exceeded $180 million versus more than $140 million in 2018.
Outlook, commentary and risks
- Management expected $15–23 million of additional pretax restructuring costs in 2020. Digital PCR system commercialization was targeted to begin in 2020; the filing provides no clear quantified revenue or earnings guidance for 2020.
- QIAGEN redirected NGS development toward its 15-year Illumina partnership for diagnostic kits and platform-agnostic consumables, ending development of new proprietary NGS instruments while continuing GeneReader customer support.
- Other stated growth priorities included QIAstat-Dx, NeuMoDx, QuantiFERON-TB, companion diagnostics and digital insights. QIAstat-Dx generated $15 million in 2019; QIAGEN reported approximately 2,500 cumulative QIAsymphony placements and nearly 1,000 QIAstat-Dx placements.
- The filing references the December 2019 COVID-19 outbreak and says a QIAstat-Dx respiratory-panel version including the coronavirus strain was created in early 2020 for potential use in China and other markets. This was a subsequent development, not a 2019 sales contribution.
- Key risks include product development delays or weak adoption, intense competition, regulatory approvals and reimbursement, dependence on research funding, acquisition integration, foreign-exchange exposure, cybersecurity and privacy, supplier or logistics disruption, debt and refinancing obligations, and potential impairment of goodwill or intangible assets. The filing also identifies Brexit-related supply-chain and currency uncertainty.
- Potential contingent acquisition payments totaled up to $179.4 million, with $162.2 million recorded at fair value at year-end. Unrecognized tax benefits were $58.0 million; management said approximately $31.4 million might be released or used within 12 months, subject to uncertainty. Litigation accruals were $0.8 million; estimated possible losses ranged from $0.3 million to $2.2 million.
- The CEO transition was significant: Peer Schatz’s contract ended September 30, 2019, and Thierry Bernard became interim CEO in October. Auditors issued unqualified opinions on the financial statements and internal control over financial reporting.
Investor verification priorities
- Reconcile the $306.6 million of reported 2019 restructuring, impairment and related charges to the income statement, cash-flow adjustments and remaining 2020 costs.
- Check cash conversion, working-capital movements and the maturity/conversion terms of $1.7 billion of debt, especially the 2021 notes and the $479.2 million undrawn facilities.
- Assess whether consumables growth and planned platform launches can offset declining instrument sales and sustain margins after the 2019 NGS strategy change.
- Track the timing and achievement of the Formulatrix digital-PCR milestones and other contingent acquisition payments, including the $134.3 million accrued for expected Formulatrix payments.
- Review the effective tax rate and recoverability of deferred tax assets, goodwill of $2.14 billion, intangible assets of $632.4 million, and the $58.0 million of unrecognized tax benefits.